Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Opal

Showing results (151-160 of 168) with videos related to

Pageof 17
Sort By:
Shock (Augusta, Ga.)|March 15, 2016
PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSISSteven M Opal, James L Ellis, Vipin Suri, et al.
Shock (Augusta, Ga.)|December 1, 2005
The activity of pathway-selective estrogen receptor ligands in experimental septic shockSteven M Opal, John E Palardy, Patricia Cristofaro, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2014
Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plagueHenry S Heine, Arnold Louie, Jeffrey J Adamovicz, et al.
Critical Care (London, England)|November 29, 2007
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infectionEmily C Lutterloh, Steven M Opal, Debra D Pittman, et al.
The Journal of Infectious Diseases|March 9, 2010
Estrogen receptor beta agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: a pharmacogenomic studyEirini Christaki, Steven M Opal, James C Keith, et al.
World Journal of Stem Cells|April 12, 2017
Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapyJorge Zorzopulos, Steven M Opal, Andrés Hernando-Insúa, et al.
The Journal of Infectious Diseases|October 12, 2014
CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitisGirish Ramachandran, Raymond Kaempfer, Chun-Shiang Chung, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2003
Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)Steven M Opal, Gary E Garber, Steven P LaRosa, et al.
Shock (Augusta, Ga.)|January 26, 2011
A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumoniaEirini Christaki, Steven M Opal, James C Keith, et al.
Annals of the American Thoracic Society|February 2, 2018
Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical TrialRoger J Lewis, Derek C Angus, Pierre-François Laterre, et al.
Pageof 17

Showing results (151-160 of 168) with videos related to

Sort By:
Pageof 17
Shock (Augusta, Ga.)|March 15, 2016
PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSISSteven M Opal, James L Ellis, Vipin Suri, et al.
Shock (Augusta, Ga.)|December 1, 2005
The activity of pathway-selective estrogen receptor ligands in experimental septic shockSteven M Opal, John E Palardy, Patricia Cristofaro, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2014
Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plagueHenry S Heine, Arnold Louie, Jeffrey J Adamovicz, et al.
Critical Care (London, England)|November 29, 2007
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infectionEmily C Lutterloh, Steven M Opal, Debra D Pittman, et al.
The Journal of Infectious Diseases|March 9, 2010
Estrogen receptor beta agonism increases survival in experimentally induced sepsis and ameliorates the genomic sepsis signature: a pharmacogenomic studyEirini Christaki, Steven M Opal, James C Keith, et al.
World Journal of Stem Cells|April 12, 2017
Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapyJorge Zorzopulos, Steven M Opal, Andrés Hernando-Insúa, et al.
The Journal of Infectious Diseases|October 12, 2014
CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitisGirish Ramachandran, Raymond Kaempfer, Chun-Shiang Chung, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2003
Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)Steven M Opal, Gary E Garber, Steven P LaRosa, et al.
Shock (Augusta, Ga.)|January 26, 2011
A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumoniaEirini Christaki, Steven M Opal, James C Keith, et al.
Annals of the American Thoracic Society|February 2, 2018
Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical TrialRoger J Lewis, Derek C Angus, Pierre-François Laterre, et al.
Pageof 17